

Taipei Bio-Innovation Park (TBIP)



Dr. Chung-Liang Chien

**Advisor, Century Biotech Development
Corporation (TBIP)**

**CEO, Institute for Biotechnology and
Medicine Industry (IBMI)**

Professor, National Taiwan University

2024.09.04

Agenda for ICEP AIT delegates at TBIP

Time	Organization	Speaker
15:30-15:40	Taipei BioInnovation Park (TBIP)	Dr. Chung-Liang Chien, Advisor
15:40-15:50	AetherAI 雲象科技股份有限公司	Dr. Joe Yeh, CEO
15:50-16:00	SYNCELL 新析生物科技股份有限公司	Dr. Jung-Chi Liao, CEO
16:00-16:10	TBMC 臺灣生物醫藥製造股份有限公司	Dr. Wei-Kuang Chi, CTO
16:10-16:30	Q&A	All Speakers

Time	Site Visit/Location	Guide
16:35-16:55 (Group A)	OBI Pharma 台灣浩鼎生技股份有限公司 (6F & 7F)	OBI Pharma team
16:35-16:55 (Group B)	TBIP Incubator Center (15F)	Dr. Jenny Yang (Managing Director)
17:00	Closing ceremony /2F	ICEP AIT Teams

Taipei BioInnovation Park (TBIP)





Taipei BioInnovation Park is Taiwan's first BOT development project for the biotech industry. It serves as a key core base, promoting nationwide biotech integration and international collaboration while nurturing talent and fostering innovation.

TBIP is a biotechnology industrial park with 17 floors (**14F-17F are designed as the Incubation Center**). The park is located near the NanGang Station, a transportation hub for high-speed rail and MRT.

世康開發股份有限公司

Century Biotech Development Corporation



Floor Lay Out

14-17F

Innovation Incubation Center

6-13F

Lab/Pilot Plant Office Space

3-5F

Office Space

1-2F

Service & Meeting Area



PharmaEssentia



MERCK



Acepodia

NaviFUS



ELIXIRON



AnnJi



EXCELSIOR



GNTbm 華上生醫



Intelligene 智新生技



TEKCORE



Royal Host





雲象科技 **aetherAI** provides **solutions for digital pathology and AI-powered diagnostic support** to help pathologists perform more effectively, realizing the true potential of the digital transformation.



新析生技 **.SYNCELL**'s Microscoop spatial proteomics technology can turn a microscope into a "Microscoop" - the world's first in-cell "pickable" microscope that applies **an AI algorithm to selectively recover proteins and nucleic acids** from a specified subcellular location.



臺灣生物醫藥製造 **Taiwan Bio-Manufacturing Corporation (TBMC)** is a pioneering **CDMO** focusing on advancing biomanufacturing innovations. TBMC is developing an automated platform for the **mass production of MSC and cancer immunotherapy cell therapy drugs**. TBMC also offer comprehensive one-stop services including IRB planning and writing, process development, QC method establishment, functional verification, CMC document preparation, as well as clinical trial design.



臺灣浩鼎 **OBI Pharma** is a global clinical stage oncology company that is headquartered in Taiwan. The core value of OBI lies in its passion to develop and deliver a portfolio of **unique antibody-drug conjugates (ADC) drugs** for patients, in addition to its promising Globo series (e.g., Globo H) of **cancer therapeutic vaccines**.

Cell Therapy-related Companies



艾萬霖生技
ExoOne Bio

艾萬霖生技 ExoOne Biotech is committed to developing the clinical application of **exosomes** and focusing on the treatment of **degenerative diseases**. The exosomes are mainly isolated from the mesenchymal stem cells of the umbilical cord (**UC-MSCs**).



Precision Biotech

精準生技 Precision Biotech is focusing on the **immune cell (NK/NKT) therapy for cancers**. They also provide services for cell processing and banking. IRB planning and writing, CMC document preparation, as well as clinical trial design.



高端疫苗 MVC is focusing on the development and mass production of vaccines and biologics. MVC have PIC/S GMP certified cell culture mass production capabilities, and **target infectious diseases to develop novel vaccines** and affordable **biosimilar drugs** via international alliances.



LumiSTAR

昱星生技 LumiSTAR is developing a pipeline of innovative cell therapies based on **induced pluripotent stem cell (iPSC)** technology. LumiSTAR also equipped with iPSC and bioimaging-based high throughput drug screening platform to develop new drugs.



育世博 Acepodia is developing innovative, highly effective cell therapies for cancer that are broadly accessible for patients. By arming our powerful **cancer-killing cells** with the tumor-targeting technology, **Antibody-Cell Conjugation (ACC)**, Acepodia believes it can develop powerful, accessible cell therapies for patients with cancer.



瑞福生醫 Cytopacx is focusing on the neural regeneration and tissue engineering with **exosome technology**. Cytopacx is also providing a health supplement with combination of probiotics formulated with useful skin activating factors to improve the skin condition.



美商永生 Stemcyte provides the private **cord blood banking** service also offers **Newborn Genetic Analysis (NGA)** which identifies any DNA irregularities and screens for over 200 health disorders.



禾豐醫 LKST Biosciences is Taiwan dealer of LONZA COCON (The **Cell Therapy** Manufacturing Platform) and CYTEK Biosciences (Full spectrum flow cytometry systems). LKST Biosciences provide researchers with advanced cell culture solutions to support the R&D for cell therapy.

Agenda for the ICEP AIT delegates at TBIP

Time	Organization	Speaker
15:30-15:40	Taipei BioInnovation Park (TBIP)	Dr. Chung-Liang Chien, Advisor
15:40-15:50	AetherAI 雲象科技股份有限公司	Dr. Joe Yeh, CEO
15:50-16:00	SYNCELL 新析生物科技股份有限公司	Dr. Jung-Chi Liao, CEO
16:00-16:10	TBMC 臺灣生物醫藥製造股份有限公司	Dr. Wei-Kuang Chi, CTO
16:10-16:30	Q&A	All Speakers

Time	Site Visit/Location	Guide
16:35-16:55 (Group A)	OBI Pharma 台灣浩鼎生技股份有限公司 (6F & 7F)	OBI Pharma team
16:35-16:55 (Group B)	TBIP Incubator Center (15F)	Dr. Jenny Yang (Managing Director)
17:00	Closing ceremony /2F	ICEP AIT Teams